Highlights of PBTI Coimbra Conference on PRT of Plasma & Current Opinions on Pathogen Reduction Treatment of Blood Components

Pamphilon, 2000, Viral inactivation of fresh frozen plasma, Br J Haematol, 109, 680, 10.1046/j.1365-2141.2000.02019.x Seghatchian, 2001, Current strategies for the provision of safer plasma and its derivatives; am update, Transfus Apher Sci, 25, 185, 10.1016/S1473-0502(01)00118-5 Seghatchian, 2006, Pathogen-reduction systems for blood components: the current position and future trends, Transfus Apher Sci, 35, 189, 10.1016/j.transci.2006.10.002 Bryant, 2007, Pathogen inactivation: the definitive safeguard for the blood supply, Arch Pathol Lab Med, 131, 719, 10.5858/2007-131-719-PITDSF Solheim, 2009, Chapter 51 Viral inactivation of blood components, 801 Irsch, 2010, Intercept plasma: comparability with conventional fresh frozen plasma based on coagulation function- an in vitro analysis, Vox Sang, 98, 47, 10.1111/j.1423-0410.2009.01224.x Hervig, 2010, Current debate on pathogen inactivation of platelet concentrates- to use or not to use?, Transfus Apher Sci, 43, 411, 10.1016/j.transci.2010.10.012 Hellstern, 2011, Transfus Med Hemother, 38, 65, 10.1159/000323552 Marschner, 2011, Transfus Med Hemother, 38, 8, 10.1159/000324160 Seghatchian, 2011, Transfus Med Hemother, 38, 55, 10.1159/000323786 AuBouchon, 2011, Update on the status of pathogen inactivation methods, Vox Sang, 6, 181, 10.1111/j.1751-2824.2011.01471.x Prowse, 2012, Component pathogen inactivation: a critical review, Vox Sang, 6, 11 FDA, 2012 Seghatchian, 2013, Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments, criteria of acceptability and storage lesion, Transfus Apher Sci, 49, 357, 10.1016/j.transci.2013.07.023 Rock, 2014, Theme article on SDP, Transfus Apher Sci, 25, 9, 10.1016/j.transci.2014.08.003 Goubran Salumkhe